Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -35.96% is 68% above its 5-year average of -113.46%, near the high end of its 5-year range (-275.61%–-35.96%).
38.93% above its 12-month average of -58.88%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -10.38%.
RETURN ON ASSETS (ROA)
-35.96%
RETURN ON ASSETS (ROA) AVG TTM
-58.88%
RETURN ON ASSETS (ROA) AVG 3Y
-82.10%
RETURN ON ASSETS (ROA) AVG 5Y
-113.46%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+38.93%
CURRENT VS 3Y AVG
+56.20%
CURRENT VS 5Y AVG
+68.31%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.29%
median of 679 covered companies
CURRENT VS SECTOR MEDIAN
-18.72%
vs the sector median at left
Eupraxia Pharmaceuticals Inc.
Market Cap
$266.33M
Return on Assets (ROA)
-35.96%
TTM Avg
-58.88%
3Y Avg
-82.10%
5Y Avg
-113.46%
Market Cap
$268.20M
Return on Assets (ROA)
-13.63%
TTM Avg
-10.56%
3Y Avg
-3.47%
5Y Avg
-3.69%
Market Cap
$265.45M
Return on Assets (ROA)
-34.24%
TTM Avg
-52.06%
3Y Avg
-53.17%
5Y Avg
-44.53%
Market Cap
$263.41M
Return on Assets (ROA)
-37.07%
TTM Avg
-27.27%
3Y Avg
-64.53%
5Y Avg
-52.03%
Market Cap
$262.97M
Return on Assets (ROA)
-25.09%
TTM Avg
-72.59%
3Y Avg
-80.80%
5Y Avg
-146.30%
Market Cap
$260.03M
Return on Assets (ROA)
-29.15%
TTM Avg
-33.84%
3Y Avg
-33.85%
5Y Avg
-31.54%
Market Cap
$271.73M
Return on Assets (ROA)
-134.38%
TTM Avg
-47.50%
3Y Avg
-42.91%
5Y Avg
-40.55%
Market Cap
$258.56M
Return on Assets (ROA)
-2.06%
TTM Avg
-16.77%
3Y Avg
-17.09%
5Y Avg
-12.28%
Market Cap
$256.22M
Return on Assets (ROA)
-38.25%
TTM Avg
-20.05%
3Y Avg
-26.23%
5Y Avg
-29.50%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | $266.33M | -35.96% | -58.88% | -82.10% | -113.46% |
| OraSure Technologies, Inc. (OSUR)vs › | $268.20M | -13.63% | -10.56% | -3.47% | -3.69% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $265.45M | -34.24% | -52.06% | -53.17% | -44.53% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.41M | -37.07% | -27.27% | -64.53% | -52.03% |
| Palisade Bio, Inc. (PALI)vs › | $262.97M | -25.09% | -72.59% | -80.80% | -146.30% |
| AC Immune S.A. (ACIU)vs › | $260.03M | -29.15% | -33.84% | -33.85% | -31.54% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $271.73M | -134.38% | -47.50% | -42.91% | -40.55% |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.56M | -2.06% | -16.77% | -17.09% | -12.28% |
| Century Therapeutics, Inc. (IPSC)vs › | $256.22M | -38.25% | -20.05% | -26.23% | -29.50% |
| Aurora Cannabis Inc. (ACB)vs › | $280.29M | -18.18% | -10.00% | -29.10% | -54.94% |
ROA
-36.0%
ROE
-38.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -44.78% |
| 2024-12-31 | -72.98% |
| 2023-12-31 | -139.25% |
| 2022-12-31 | -71.41% |
| 2021-12-31 | -76.73% |
| 2020-12-31 | -275.61% |
| 2019-12-31 | -224.40% |
| 2018-12-31 | -453.38% |
| 2017-12-31 | -73.90% |
